ArticleClinical and experimental immunology2009
Helminth antigen-based strategy to ameliorate inflammation in an experimental model of colitis.
Article in Clinical and experimental immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 101 citations in OpenAlex.
- Protective and therapeutic potentials of Trichinella spiralis larval antigen in murine induced colitis.Scientific reports · 2025Article
- Syphacia obvelata antigens alter the FOXP3/RORɣt expression balance in isolated peripheral blood mononuclear cells of IBD patients.Scientific reports · 2025Article
- Therapeutic potentials of Trichinella spiralis in immune disorders: From allergy to autoimmunity.Parasites, hosts and diseases · 2025Review
- Helminths in alternative therapeutics of inflammatory bowel disease.Intestinal research · 2025Review
- Molecular and biological characterization of transforming growth factor-β homolog derived from Trichinella spiralis.Scientific reports · 2024Article
- Immuno-therapeutic and prophylactic potential ofFood and waterborne parasitology · 2024Article
- Interaction between Intestinal Parasites and the Gut Microbiota: Implications for the Intestinal Immune Response and Host Defence.Pathogens (Basel, Switzerland) · 2024Review
- Extracellular Vesicles: Novel Potential Therapeutic Agents in Inflammatory Bowel Diseases.Cells · 2023Review
- Colonization with two differentTheranostics · 2023Article
- An engineered probiotic secreting Sj16 ameliorates colitis via Ruminococcaceae/butyrate/retinoic acid axis.Bioengineering & translational medicine · 2021Article
- Review
- Exposure time determines the protective effect of Trichinella spiralis on experimental colitis.Microbial pathogenesis · 2020Article
- Interventions of natural and synthetic agents in inflammatory bowel disease, modulation of nitric oxide pathways.World journal of gastroenterology · 2020Review
- Excretory/Secretory Products FromFrontiers in immunology · 2020Article
- Immunomodulatory effect of Syphacia obvelata in treatment of experimental DSS-induced colitis in mouse model.Scientific reports · 2019Article
- Role of mast cells in the generation of a T-helper type 2 dominated anti-helminthic immune response.Bioscience reports · 2019Article
- Urbanization and the gut microbiota in health and inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2018Review
- A Single Microorganism Epitope Attenuates the Development of Murine Autoimmune Arthritis: Regulation of Dendritic CellsFrontiers in immunology · 2018Article
- The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease.Frontiers in microbiology · 2018Review
- Therapeutic potential of helminths in autoimmune diseases: helminth-derived immune-regulators and immune balance.Parasitology research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is the most common and serious chronic inflammatory condition of the gut. Among the distinct T helper (Th) cell subsets, a Th1 type response is associated predominantly with Crohn's disease (CD) while helminth infections generate a strong Th2 type response. IBD is most prevalent in developed countries but rare in countries where infections with helminths are common. Thus, it has been hypothesized that infection with helminth infection influence the development of CD and recent clinical and experimental studies suggest strongly a beneficial role of helminth infection in IBD. In the present study we examined the effects of rectal submucosal administration of helminth antigens on subsequent experimental colitis. Mice were treated with Trichinella spiralis antigens prior to the induction of dinitrobenzenesulphonic acid (DNBS)-induced colitis and were killed 3 days post-DNBS to assess colonic damage macroscopically, histologically and by myeloperoxidase (MPO) activity, inducible nitric oxide synthase (iNOS) and cytokine levels. Previous treatment with T. spiralis antigens reduced the severity of colitis significantly, as assessed macroscopically and histologically, and reduced the mortality rate. This benefit was correlated with a down-regulation of MPO activity, interleukin (IL)-1beta production and iNOS expression and an up-regulation of IL-13 and transforming growth factor-beta production in colon. These results clearly show a beneficial role of local treatment with helminth antigens for experimental colitis and prompt consideration of helminth antigen-based therapy for IBD instead of infection with live parasites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.